logo
Max Fink, Champion of Electroconvulsive Therapy, Dies at 102

Max Fink, Champion of Electroconvulsive Therapy, Dies at 102

New York Times27-06-2025
Max Fink, a psychiatrist and neurologist who advanced the acceptance of electroconvulsive therapy as an option for treating severely depressed patients who do not respond to drugs or psychotherapy, died on June 15 in Westfield, Mass. He was 102.
His death, at a senior living community, was confirmed by his son, Jonathan Fink.
Dr. Fink believed that electroconvulsive therapy was a potent treatment — and shouldn't be considered a last resort — for patients who are suicidal or suffering from delusions.
'Many severely depressed patients are maintained for weeks, for months and even years on antidepressant drugs,' he told a conference on depression in Philadelphia in 1988. 'Are we not unfair when we do this to our patients when ECT remains an active and excellent treatment?'
He first witnessed the use of ECT in 1952, on his first day as a neurology and psychiatry resident at Hillside Hospital (now Zucker Hillside Hospital, a part of Northwell), in Queens. One by one, he watched as five patients — under restraints, with rubber bite-blocks in their mouths and electrodes applied to their temples — received enough electrical current to induce a grand mal seizure.
'Observing a full grand mal seizure in each patient jarred me,' he wrote in 2017 in an unpublished memoir for Stony Brook University in New York, where he worked for many years. But over the next few months, he continued, 'I had learned that ECT effectively reduced suicide thoughts, relieved negativism, aggression, depressed and manic moods. Of the hospital populations, the patients treated with electroshock improved the most.'
Although Dr. Fink was convinced of ECT's positive effects, others in the psychiatric profession weren't.
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Yahoo

time14 minutes ago

  • Yahoo

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

Claims Data Fail to Accurately Identify MI Types
Claims Data Fail to Accurately Identify MI Types

Medscape

time15 minutes ago

  • Medscape

Claims Data Fail to Accurately Identify MI Types

TOPLINE: Clinical auditing reveals significant misclassification in administrative codes for myocardial infarction (MI), with only 39% of type 1 (T1MI) codes and 72% of type 2 (T2MI) codes for the condition accurately reflecting the true diagnosis, researchers found. Nearly half of patients coded for T1MI had T2MI, whereas 26% of T2MI codes represented myocardial injury. METHODOLOGY: Researchers identified 350 randomly sampled patients with T1MI codes and 350 patients with T2MI codes during inpatient encounters using the International Statistical Classification of Diseases and Related Health Problems-10th Revision. The analysis included patients aged 65 years and older from October 1, 2017, to May 9, 2024, within eight hospitals in the Mass General Brigham system. Using the 4th Universal Definition of MI, the researchers reviewed the clinical encounters to assess evidence of plaque erosion or thrombus vs oxygen demand-supply imbalance. A second physician review was conducted for 146 challenging and 146 nonchallenging cases. TAKEAWAY: Among the 350 patients coded as having had T1MI, clinical adjudication revealed 138 (39%) as correctly diagnosed; 159 (45%) in fact had T2MI, and 35 (10%) had myocardial injury. Of the 350 patients coded as having had T2MI, 251 (72%) were confirmed, four (1%) were found to have T1MI, and 91 (26%) had myocardial injury. A second physician review demonstrated a high degree of agreement with the initial review, with a 94% agreement in nonchallenging cases and 86% in challenging cases. Hospitals equipped with vs without cardiac catheterization laboratories showed significantly lower misclassification rates (43% vs 58%; P = .0298). IN PRACTICE: 'Among individuals assigned a T1MI claims code, nearly one half have T2MI and many others have myocardial injury; fewer than one half have true T1MI,' the researchers reported. 'Our results also confirm and extend previous work showing that among those with T2MI codes, slightly more than one half have true T2MI, with most of the misclassification related to myocardial injury rather than T1MI. This has critically important implications for epidemiology and public policy' related to acute myocardial infarction. SOURCE: The study was led by Andrea Martinez, MD, of the Department of Medicine at Massachusetts General Hospital, Boston. It was published online on July 21 in Journal of the American College of Cardiology. LIMITATIONS: The results may not be generalized to other hospital systems and countries, where patterns of misclassification might differ. The researchers noted external validity assessment across multiple healthcare systems and in countries that have already introduced International Classification of Diseases-11th revision coding would be beneficial. While patterns of misclassification might have changed over time, the analysis was intentionally restricted to the period when codes for both T1MI and T2MI were available. DISCLOSURES: The study received support through a grant to Jason Wasfy from the Massachusetts General Hospital Executive Committee on Research. Individual authors reported receiving other grants and support, including grants from industry. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

COVID-19 cases are on the rise in MA, CDC says. What to know about 'Nimbus' strain.
COVID-19 cases are on the rise in MA, CDC says. What to know about 'Nimbus' strain.

Yahoo

time18 minutes ago

  • Yahoo

COVID-19 cases are on the rise in MA, CDC says. What to know about 'Nimbus' strain.

COVID-19 numbers are rising in Massachusetts, and in states across the country. "COVID-19 laboratory percent positivity is increasing nationally," according to the Centers for Disease Control and Prevention (CDC) website. "Emergency department visits for COVID-19 are increasing among young children 0-4 years old," though the CDC noted that emergency room visits are "low" overall. The latest COVID-19 strain is known as "Nimbus." Here's what to know. Are COVID-19 numbers increasing in Massachusetts? The CDC website has evaluated the issue in each state and determined cases in Massachusetts are likely rising. In Massachusetts, there is an 85.8% chance that COVID-19 numbers are increasing, according to the CDC. The Massachusetts Department of Public Health (DPH) reported that as of June 28, there were 377 confirmed cases of COVID and 77 unconfirmed cases. No COVID-19 deaths were reported at the time. The data stops in June because the Massachusetts DPH "ended data collection for the 2024-2025 viral respiratory season on June 28, 2025, and routine updates to their dashboard for the 2025-2026 season will resume later this summer." What is the current COVID-19 strain 'Nimbus?' As of early June, the new strain known as NB.1.8.1, or "Nimbus," made up 37% of COVID-19 cases nationwide. Variant NB.1.8.1 was first detected in China in January 2025 but accounted for about 0% of cases in the United States until May. The World Health Organization added at the time that currently approved COVID-19 vaccines are "expected to remain effective to this variant against symptomatic and severe disease." Virologists describe Nimbus as a 'slightly upgraded' version of its predecessor. While there is no evidence it causes more severe disease, it appears to be highly transmissible. What are the symptoms of Nimbus? Reported symptoms of NB.1.8.1 are similar to other COVID-19 strains, but one distinctive complaint is a severe sore throat, sometimes described as 'razor-blade throat fatigue.' Other symptoms may include: Mild cough Fever Muscle aches Nasal congestion Are vaccines still effective? Health experts say that updated COVID-19 vaccines remain the best protection against severe illness. Vaccination rates vary widely by state, and health officials continue to urge eligible individuals to stay current with their shots. How can people get tested? People can either take an at-home test or they can see their respective doctors. (This story was updated because an earlier version included an inaccuracy.) This article originally appeared on COVID cases on rise in MA, CDC says. What to know about latest strain Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store